EUVIMEDEUVIMED entdecken
LeserbriefKommentarSystematische Übersicht

A comment on ‘Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials’

Ronald M Goldenberg iD

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15588 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Ronald M Goldenberg. Beteiligte Einrichtung: LMC Diabetes & Endocrinology, Vaughan, Ontario, Canada. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Thyroid Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 6 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.15588. Data sharing is not applicable to this article as no new data were created.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsThyroid NeoplasmsHumansDiabetes Mellitus, Type 2Hypoglycemic AgentsMeta-Analysis as TopicRandomized Controlled Trials as TopicRisk FactorsSystematic Reviews as Topic

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agents

Autor:innen und Institutionen

  • LMC Diabetes & Endocrinology, Vaughan, Ontario, Canada.

ORCID-Profile: Ronald M Goldenberg

Zitieren

APA

Goldenberg, R. M. (2024). A comment on ‘Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials’. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15588

Vancouver

Goldenberg RM. A comment on ‘Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials’. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15588

BibTeX
@article{Goldenberg2024,
  author = {Goldenberg, Ronald M},
  title = {A comment on ‘Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials’},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15588}
}
Kostenlos starten →